NEW YORK, June 25, 2013 /PRNewswire/ --
Dynavax Technologies Corporation
Lifshitz Law Firm announces that a class action suit was filed in the United States District Court for the Northern District of California, alleging that Dynavax Technologies Corporation ("Dynavax" or the "Company") (DVAX) issued false and misleading statements to investors between April 26, 2012 and June 10, 2013, inclusive (the "Class Period"). On June 10, 2013, the Company disclosed that in a meeting with the FDA over its biologic license application for hepatitis-B vaccine Heplisav, the FDA expressed that it wanted additional safety data from more patients before approving the drug. The FDA further expressed that analyzing Heplisav for smaller groups of patients did not fully address its concerns and that it would like to see additional safety trials. Moreover, as previously noted by the FDA, the Company disclosed that there were ongoing concerns regarding Dynavax's manufacturing and testing of Heplisav.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts